New tool helps predict CAR T therapy outcomes for lymphoma patients

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, with its National Medical Center in Los Angeles ranked among the nation’s top 5 cancer centers by U.S. News & World Report, and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient’s likely response to chimeric antigen receptor (CAR) T cell therapy before starting the treatment, according to study results published today in Nature Medicine.

Leave a Reply